MicroVue™ SC5b-9 Plus EIA

The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the amount of the SC5b-9 complex in specimens.

Product Specifications

Citations	97
Specimen	Serum 10 μL, EDTA or Citrated Plasma 50 μL
LLOQ	8.8 ng/mL
ULOQ	N/A
Assay Time	2 hours
Cross Reactivity	African Green Monkey, Baboon, Cynomolgous monkey, Pigtail Monkey, Rabbit, Rhesus monkey

Technical Documents

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.

Catalog Number	A020
Catalog Number (CE)	A029
Size	96 wells/test
Price (USD)	$725.00
Price (EURO)	650,00 €

Request an Order

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	contact-us@quidelortho.com
EU Email	contact-emea@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the amount of the SC5b-9 complex in specimens.
Size	96 wells/test
Form	96 well plate with 12 eight-well strips in a resealable foil pouch
Specimen	Serum 10 μL, EDTA or Citrated Plasma 50 μL
Limit of Detection (LOD)	3.7 ng/mL
Lower Limit of Quantitation (LLOQ)	8.8 ng/mL
Upper Limit of Quantitation (ULOQ)	N/A
Intra Assay	1.6–6.8%
Inter Assay	5.0–13.1%
Standards	5
Controls	2
Sample Values	None
Assay Time	2 hours
Cross Reactivity	African Green Monkey, Baboon, Cynomolgous monkey, Pigtail Monkey, Rabbit, Rhesus monkey
Storage	Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details.
Background	The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC. For purposes of this document, we refer to all forms of stable Terminal Complement Complex interchangeably as TCC and SC5b-9, recognizing that other complement regulatory proteins, like Clusterin, also form these stable complexes and are detectable in the SC5b-9 Plus assay. The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the concentration of TCC thereby giving an indication of the status of the terminal complement pathway in the specimen. It uses a monoclonal antibody to the C9 ring of TCC to capture the complex. The trapped TCC is subsequently detected with HRP-conjugated antibodies that bind to antigens of the SC5b-9 complex. This test, which provides a rapid, highly specific and quantitative procedure for measuring TCC levels, is designed for investigations studying the role or status of terminal complement pathway activation in numerous research settings, and for monitoring the generation of SC5b-9 complexes in vivo or in vitro.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
Complement activation in patients with neuromyelitis optica	2014	ELISA	Human	Plasma	Neuromyelitis optica
Pentraxin 3 recruits complement factor H to protect against oxidative stress-induced complement and inflammasome overactivation.	2016	ELISA	Human	ARPE-19 Cells
Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes.	2017	ELISA	Human	Serum	Diabetes
Complete kinetic follow-up of symptoms and complement parameters during a hereditary angioedema attack.	2017	ELISA	Human	Plasma	Hereditary Angioedema
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.	2018	ELISA	Human	Serum	Microvesicles with heme
A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity.	2019	ELISA	Human	Plasma	Chronic Lymphocytic Leukemia
A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity.	2019	ELISA	Human	Serum	Chronic Lymphocytic Leukemia
Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy	2019	ELISA	Human	Urine	Diabetic nephropathy
Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.	2019	ELISA	Human	Plasma	ANCA-AAV
Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.	2019	ELISA	Human	Plasma	aHUS
Complement factor H contributes to mortality in humans and mice with bacterial meningitis.	2019	ELISA	Human	CSF	Bacterial meningitis
Complement fragments are biomarkers of antibody-mediated endothelial injury.	2019	ELISA	Human	Plasma	Antibody-mediated endothelial injury
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.	2020	ELISA	Human	Plasma	FSGS
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.	2020	ELISA	Human	Serum	FSGS
Cloaking Silica Nanoparticles with Functional Protein Coatings for Reduced Complement Activation and Cellular Uptake.	2020	ELISA	Human	Serum	SiNP coated proteins
Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy.	2020	ELISA	Human	Plasma	COVID-19
Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis.	2019	ELISA	Human	Urine	FSGS, MN, IgAN, LN, AAV, or MPGN
Complement activation and endothelial perturbation parallel COVID-19 severity and activity.	2020	ELISA	Human	Plasma	COVID-19
Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.	2020	ELISA	Human	Serum	Lupus Nephritis, Thrombotic Microangiopathy
Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.	2020	ELISA	Human	Urine	Lupus Nephritis, Thrombotic Microangiopathy
P-MAPA, a Fungi-Derived Immunomodulatory Compound, Induces a Proinflammatory Response in a Human Whole Blood Model.	2020	ELISA	Human	Plasma	P-MAPA
Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation.	2020	ELISA	Human	Plasma	Thrombotic Microangiopathy - TA
Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state.	2021	ELISA	Human	Serum	COVID-19
Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.	2021	ELISA	Human	Glomular Endothelial Cells	Supernatent
CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis	2021	ELISA	Human	Plasma	MPGN
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.	2021	ELISA	Human	Plasma	C3G
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.	2021	ELISA	Human	Urine	C3G
Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy	2021	ELISA	Human	Plasma	Thrombotic Microangiopathy - TA
Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.	2021	ELISA	Human	Plasma
Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports.	2021	ELISA	Human	Plasma	Glomerulonephritis
The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare.	2021	ELISA	Human	Plasma	Lupus Nephritis
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.	2021	ELISA	Human	Plasma	Cancer, COVID-19
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.	2021	ELISA	Human	Plasma	COVID-19
Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.	2021	ELISA	Human	Serum	aHUS
Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.	2021	ELISA	Human	Urine	aHUS
Severe COVID-19 is associated with hyperactivation of the alternative complement pathway.	2021	ELISA	Human	Plasma	COVID-19
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.	2022	ELISA	Human	Plasma	aHUS
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.	2022	ELISA	Human	Plasma	COVID-19
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.	2021	ELISA	Human	Plasma	COVID-19
Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.	2022	ELISA	Human	Plasma	COVID-19
Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.	2022	ELISA	Human	Serum	COVID-19
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets.	2022	ELISA	Human	Plasma	Antiphospholipid syndrome
Mechanism of Borrelia immune evasion by FhbA-related proteins	2022	ELISA	Human	Plasma	Borrelia hermsii
Complement Activation in Patients With Heat-Related Illnesses: Soluble CD59 Is a Novel Biomarker Indicating Severity of Heat-Related Illnesses.	2022	ELISA	Human	Plasma	Heat-related illnesses
Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis.	2022	ELISA	Human	Serum	Myeloperoxidase-ANCA-associated glomerulonephritis
Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis.	2022	ELISA	Human	Urine	AAV, FSGS, IgAN, MN, and LN
Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.	2022	ELISA	Human	Plasma	COVID-19
Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System.	2022	ELISA	Human	Whole Blood	B. jararaca venom
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.	2022	ELISA	Human	Plasma	Thrombotic Microangiopathy - DI
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.	2022	ELISA	Human	Plasma	Thrombotic Microangiopathy - DI
Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients.	2022	ELISA	Human	Plasma	COVID-19
Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.	2022	ELISA	Human	Plasma	Hemodialysis
Complement activation during cardiopulmonary bypass and association with clinical outcomes.	2022	ELISA	Human	Plasma	Cardiopulmonary bypass
Indices of complement activation and coagulation changes in trauma patients	2022	ELISA	Human	Plasma	Trauma
C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome.	2022	ELISA	Human	Plasma	COVID-19
Serum and plasma levels of Ba, but not those of soluble C5b-9, might be affected by renal function in chronic kidney disease patients.	2023	ELISA	Human	Plasma, Serum	Glomerulonephritis
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury	2009	ELISA	Human	ARPE-19 Cells
Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease	2011	ELISA	Human	Serum
Heightened measures of immune complex and complement function and immune complex-mediated granulocyte activation in human lymphatic filariasis	2011	ELISA	Human	Plasma	Lymphatic filariasis
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function	2012	ELISA	Human	Serum	GEnCs and HUVEC exposed
Elevated Properdin and Enhanced Complement Activation in First-Degree Relatives of South Asian Subjects With Type 2 Diabetes	2012	ELISA	Human	Plasma
Complement activation in pediatric patients with recurrent acute otitis media	2013	ELISA	Human	Ear Fluid (MEE)
Complement activation in pediatric patients with recurrent acute otitis media	2013	ELISA	Human	Serum
Genetic variation and cerebrospinal fluid levels of mannose binding lectin in pneumococcal meningitis patients.	2013	ELISA	Human	CSF
Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent.	2013	ELISA	Human	Serum
In Vitro Hematological and In Vivo Vasoactivity Assessment of Dextran Functionalized Graphene	2013	ELISA	Human	Plasma
Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial	2014	ELISA	Human	Serum
Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center	2014	ELISA	Human	Plasma	Lupus Nephritis
Defining the complement biomarker profile of C3 glomerulopathy	2014	ELISA	Human	Plasma	C3G
Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum	2014	ELISA	Human	Serum	SPIO nanoworms
Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome	2015	ELISA	Human	Plasma	Stx-HUS
A serine protease isolated from the bristles of the Amazonic caterpillar, Premolis semirufa, is a potent complement system activator.	2015	ELISA	Human	Serum	Premolis semirufa caterpillar bristle extract
Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis	2014	ELISA	Human	CSF	Listeria meningitis
Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis	2015	ELISA	Human	Plasma
Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness	2015	ELISA	Human	Serum
In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles	2016	ELISA	Human	Serum	Nanoparticles incubated
Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.	2016	ELISA	Human	Serum
Inflammatory Response in Preterm and Very Preterm Newborns with Sepsis	2016	ELISA	Human	Serum
Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.	2016	ELISA	Human	Serum
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation	2016	ELISA	Human	Plasma	Imprime yeast treated
High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients	2017	ELISA	Human	Peritoneal dialysis fluid
Brain injury with systemic inflammation in newborns with congenital heart disease undergoing heart surgery	2017	ELISA	Human	Serum	Trauma, newborn brain
Effect of Immobilized Antithrombin III on the Thromboresistance of Polycarbonate Urethane	2017	ELISA	Human	Serum
Immunological response to nitroglycerin-loaded shear-responsive liposomes in vitro and in vivo	2017	ELISA	Human	Serum
Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway	2017	ELISA	Human	Plasma	ANCA-AAV
rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs	2018	ELISA	Human	Serum	Fc activation
Venom from Bothrops lanceolatus, a Snake Species Native to Martinique, Potently Activates the Complement System	2018	ELISA	Human	Serum	B. lanceolatus venom
Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura.	2020	ELISA	Human	Plasma	Immune‐mediated thrombotic thrombocytopenic purpura
Sensitivity and Specificity of plasma and urine complement split products as indicators of lupus disease activity	1996	ELISA	Human	Plasma	Systemic Lupus Erythematosus
Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes.	2023	ELISA	Human	Plasma	Diabetes
Persistent complement dysregulation with signs of thromboinflammation in active Long Covid.	2023	ELISA	Human	Serum	COVID-19
Decrease in multiple complement proteins associated with development of islet autoimmunity and type 1 diabetes.	2024	ELISA	Human	Plasma	Diabetes, Type 1
Persistent complement dysregulation with signs of thromboinflammation in active Long Covid	2024	ELISA	Human	Serum	COVID-19
Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 Glomerulopathy	2024	ELISA	Human	Plasma	C3G
A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease	2024	ELISA	Human	Urine	FSGS, MCD
Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model	2017	ELISA	Mouse	Serum

Certificate of Analysis

Showing results for

No results found for